| Aug 13 |
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
|
| Aug 8 |
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Carisma Therapeutics GAAP EPS of -$0.27 beats by $0.03, revenue of $9.2M beats by $5.28M
|
| Aug 8 |
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 6 |
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
|
| Aug 6 |
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024
|
| Aug 3 |
Can Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?
|
| Jun 28 |
Carisma jumps as drug discovery under Moderna deal leads to $2M payment
|
| Jun 27 |
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
|
| Jun 26 |
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
|
